Anti-Siglec-2/CD22 Antibody (NCI m972) is a fully human IgG1 kappa monoclonal antibody targeting Siglec-2 (CD22). Identified via phage display technology, this product binds specifically to Ig-like domains 5 to 7 of CD22 with an apparent affinity of approximately 15 nM. As CD22 is a specific surface marker for B-cell malignancies (e.g., ALL, NHL), NCI m972 offers low immunogenicity and is widely used for researching the development of antibody-drug conjugates (ADCs), chimeric antigen receptor T-cells (CAR-T), and targeted imaging agents.